Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases

Shaarawy, Mohamed; Darwish, Nabil A.; Abdelaziz, Omar

doi:10.1016/1071-5576(95)00036-4

Cited by 2 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It might be due to sIL-2R could combine with IL-2 and then hinder IL-2 to interact with IL-2R expressed on lymphocytes. Shaarawy et al (95) found the concentration of descendence in IL-2 and asendence in sIL-2R in sera of patients with molar pregnancy and choriocarcinoma, especially in all high-risk choriocarcinoma cases, extremely high sIL-2R was found. This findings suggested that cellular immune reactivity was suppressed in patients with GTD patients and sIL-2 may be one of biomarkers for high-risk choriocarcinoma.…”

Section: Suppressive Cytokinesmentioning

confidence: 97%

Immunobiology of gestational trophoblastic diseases

Wang¹,

Fu²,

Freedman³

et al. 2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

Gestational trophoblastic diseases (GTDs) comprise a group of interrelated diseases characterized by development after gestation, widespread metastases, and high curability with chemotherapy. The good prognosis of GTDs is considered partly a result of the host immune response to paternal antigens expressed on trophoblastic cells. In this study, we review current understanding of the immunobiology of GTDs. First of all, we describe the microenvironment between trophoblastic cells and subpopulation of immune cells. Second, immunogenetics, immune microenvironment around abnormal trophoblast, and mechanism of GTDs escaping from maternal immune system surveillance were also discussed. Third, we propose the possible immunotherapy for persistent GTDs, particularly the vaccine designed on human chorionic gonadotrophin, which is generally accepted as a tumor marker for GTDs diagnosis. Due to the low incidence of GTDs and high response to chemotherapy, there have been few literatures about immunobiologic characteristics of GTDs compared with the other gynecologic malignancies, such as ovarian cancer, but the immunologic behavior of GTDs should be explored for further understanding of the etiology of these diseases and to help designing immunotherapeutic strategies for persistent GTDs.

show abstract

Section: Suppressive Cytokinesmentioning

confidence: 97%